Why Compounding Access Is Not an Established Path Positioning in the Metabolic Medicine Conversation For physicians fielding patient questions about 5-amino-1MQ, the appropriate framing: Promising mechanism with solid preclinical rationale Early clinical development human efficacy and safety not yet well characterized No legitimate clinical access pathway in the United States as of 2026 Alternative evidence-based options exist for the underlying metabolic optimization goals patients typically pursue Key Takeaways 5-amino-1MQ is a small-molecule NNMT inhibitor, not a peptide
The vitamin may, however, be offered orally
Recommend 100% Great service and great product
Keep vials protected from light, in their original packaging or wrapped in foil
At our naturopathic clinic in Scottsdale, AOD 9604 is often combined with hormone optimization, IV therapy, nutrition counseling, and other peptides for a synergistic effect
Treatment reduces circulating markers of metabolic dysfunction and inflammation, creating a more favorable metabolic environment that supports insulin sensitivity and glucose regulation
